|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results showed that: (1) APP/PS1-AD mice had lower spontaneous alternation in the Y-maze than wild-type (WT) mice, and this was significantly reversed by AVP(4-8); (2) the prolonged escape latency of APP/PS1-AD mice in the Morris water maze was significantly decreased by AVP(4-8), and the decreased swimming time in target quadrant recovered significantly after AVP(4-8) treatment; (3) in vivo hippocampal LTP induced by high-frequency stimulation had a significant deficit in the AD mice, and this was partly rescued by AVP(4-8); (4) AVP(4-8) significantly up-regulated the expression levels of postsynaptic density 95 (PSD95) and nerve growth factor (NGF) in the hippocampus of AD mice.
|
31605298 |
2020 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Initial efforts attempted to use NGF agonistically for Alzheimer's disease and neuropathies.
|
31026504 |
2020 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This change along with an increased TrkA/p75<sup>NTR</sup> ratio of nerve growth factor receptors in the hippocampus may contribute to increased density of immature neurons that we observed at the progressive stage of AD-like pathology in OXYS rats.
|
30415068 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The released NGF exhibits a substantial neuroprotective effect in differentiated rat pheochromocytoma PC12 cells against amyloid-beta (Aβ)-induced cytotoxicity, which is associated with Alzheimer's disease.
|
31482695 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The cross-talk between NGF and insulin pathways downstream the insulin receptor suggests novel potential therapeutic targets to slow cognitive decline in AD and diabetes-related brain insulin resistance.
|
29736736 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve Growth Factor (NGF) is a therapeutic candidate for Alzheimer's disease, based on its well known actions on basal forebrain cholinergic neurons.
|
30391352 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Further, gradual dysregulation of neurotrophic factors like NGF and brain derived neurotrophic factor (BDNF) have been reported during AD development thus intensifying further research in targeting these factors as disease modifying therapies against AD.
|
30804738 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
NGF deficiency in the basal forebrain precedes degeneration of basal forebrain cholinergic neurons in Alzheimer's disease, contributing to memory decline.
|
31301255 |
2019 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We have previously shown that the expression of pro-nerve growth factor (proNGF) was significantly increased, nerve growth factor (NGF) level was decreased, and the expression of p75<sup>NTR</sup> was enhanced in Alzheimer's disease (AD) hippocampal samples.
|
31430874 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, to identify effective therapeutic agents for AD, we investigated the neuroprotective effects of two naturally occurring retinoid X receptor (RXR) agonists (SPF1 and SPF2), isolated from the root of Sophora tonkinensis Gagnep., on the Aβ<sub>25-35</sub>-induced cytotoxicity against nerve growth factor-differentiated rat pheochromocytoma (PC12) cells.
|
30377903 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of GM6 in a mouse model of AD before the development of amyloid plaques and determined how this treatment affected the accumulation of Aβ peptide and related pathologic changes (e.g., inflammation, nerve growth factor (NGF) expression, cathepsin B, and memory impairment).
|
30798443 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Those results strongly suggest that SpBMP-9 plus NGF or bFGF are promising therapeutic combinations against AD that required further attention.
|
29341901 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This work demonstrates a new concept of using thermoresponsive and biodegradable linear-dendritic nanoparticles for thermally targeted and sustained release of NGF and other protein drugs for the treatment of Alzheimer's disease and other neurological disorders.
|
29320631 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
According to much research, neurodegeneration and cognitive decline in Alzheimer disease (AD) are correlated with alternations of neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor.
|
29114922 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In a multicenter phase 2 trial, 49 participants with mild to moderate AD were randomly assigned in a 1:1 ratio to receive stereotactically guided intracerebral injections of AAV2-NGF or sham surgery.
|
29582053 |
2018 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Although data from post-mortem brains were not always consistent across studies, most studies suggested decreased BDNF and increased (pro)NGF levels in hippocampus and neocortex of patients with AD.
|
29956088 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Exposure of NGF-producing cells to CSF from AD patients showed significantly reduced NGF-release as compared to CSF from LBD or SCI patients.
|
30092220 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer's disease.
|
29625607 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) models were established by injecting Aβ(1-42) into the rat hippocampus and the effects of learning and memory were observed by a Morris water maze test, immunohistological alterations, and correlative indicators covering nerve growth (brain-derived neurotrophic factor, glial-cell-derived trophic factor, and nerve growth factor), interleukin 1β, tumor necrosis factor, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), glial fibrillary acidic protein (GFAP), and microglial CD11b in AD rats.
|
29714500 |
2018 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to validate the association of the five AD-associated variants, 8-oxoguanine DNA glycosylase 1 (<i>OGG1</i>) rs1052133, bridging integrator 1 rs744373, sortilin-related receptor 1, rs1133174, presenilin 2 rs8383, and nerve growth factor rs6330, in the Xinjiang Chinese population.
|
30214536 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Synthetic peptides that can act as NGF receptor agonists (NGF mimetics) are known to attenuate neurodegenerative pathologies in experimental models of Alzheimer's disease and Parkinson's disease; however, the existence of plant-based NGF mimetics is uncertain.
|
29955238 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Oligomeric Aβ is main pathologic species in AD and NGF deprivation is relevant for both developmental as well as pathologic neuron death.
|
29499358 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Decreased cortical NGF immunocytochemical scores of AD-like model were increased by CE (p<0.05).
|
28390878 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review covers the main therapeutic approaches that have been developed for NGF delivery targeting the brain, from polymeric implants to gene and cell-based therapies, focusing on the role of nanoparticulate systems for the sustained release of NGF in the brain as a neuroprotective and disease-modifying approach toward AD.
|
28351757 |
2017 |